Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway (Q40395107)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 2005

Language	Label	Description	Also known as
English	Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway	scientific article published on September 2005

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway (English)

1 reference

Europe PubMed Central

20 September 2017

author name string

Yao Q

1

1 reference

Europe PubMed Central

20 September 2017

Nishiuchi R

2

1 reference

Europe PubMed Central

20 September 2017

Kitamura T

3

1 reference

Europe PubMed Central

20 September 2017

Kersey JH

4

1 reference

Europe PubMed Central

20 September 2017

publication date

1 September 2005

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

19

1 reference

Europe PubMed Central

20 September 2017

9

1 reference

Europe PubMed Central

20 September 2017

1605-1612

1 reference

Europe PubMed Central

20 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403881

0 references

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

The roles of FLT3 in hematopoiesis and leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

The role of FLT3 in haematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

FLT3: ITDoes matter in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Hsp90 inhibitors as novel cancer chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Killing the messenger: short RNAs that silence gene expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403881

1 reference

Europe PubMed Central

20 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40395107&oldid=2125513583"